The Global Health Body Issues Alert Over Acute Shortage of Weight-Loss Jabs
Less than a tenth of people eligible to benefit from GLP-1 drugs such as Wegovy are able to get them, caution the WHO as it publishes its initial advice on the drugs.
Considering more than one billion individuals worldwide currently living with obesity, it is urging increased and just availability to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our latest guidance recognises that excess weight is a chronic disease that can be managed with holistic and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key hurdles to broad availability to the injections that can aid individuals in losing considerable body mass, notes the body.
Skinny Jab Supply Crisis
Even in the present most optimistic outlook, the manufacturing of these medications could only cover around 100 million people – fewer than 10% of those who need them, according to the health organization.
The recommendation calls on governments and firms to expand access, via measures including licensing agreements.
A patent on a key compound – the primary component of a leading brand – is set to lapse in multiple nations in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs replicate a natural hormone to reduce digestion speed, curb appetite and boost satiety so people eat less.
Patients usually see weight reduction within a few weeks of commencing the weekly injections.
Evidence indicates patients may put most of the weight back on within a year of halting the drug, as their normal appetite come back.
Being overweight or obese elevates your likelihood for experiencing health problems, including diabetes, heart disease, brain attack, and certain cancers.
Obesity impacts people in all nations and was linked to over three and a half million fatalities worldwide in 2024, according to the health agency.
